CRISPR Therapeutics AG (CRSP) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...
Researchers have uncovered a serious side effect of using the CRISPR-Cas gene scissors. A molecule designed to make the process more efficient destroys parts of the genome.